Background The evidence linking vitamin D (VitD) levels and spontaneous intracerebral hemorrhage (ICH) remains inconclusive. We tested the hypothesis that lower genetically determined VitD levels are associated with higher risk of ICH. Methods and Results We conducted a 2 sample Mendelian Randomization (MR) study using publicly available summary statistics from published genome-wide association studies of VitD levels (417 580 study participants) and ICH (1545 ICH cases and 1481 matched controls). We used the inverse-variance weighted approach to generate causal estimates and the MR Pleiotropy Residual Sum and Outlier and MR-Egger approaches to assess for horizontal pleiotropy. To account for known differences in their underlying mechanism, we implemented stratified analysis based on the location of the hemorrhage within the brain (lobar or nonlobar). Our primary analysis indicated that each SD decrease in genetically instrumented VitD levels was associated with a 60% increased risk of ICH (odds ratio [OR], 1.60; [95% CI, 1.05-2.43]; =0.029). We found no evidence of horizontal pleiotropy (MR-Egger intercept and MR Pleiotropy Residual Sum and Outlier global test with >0.05). Stratified analyses indicated that the association was stronger for nonlobar ICH (OR, 1.87; [95% CI, 1.18-2.97]; =0.007) compared with lobar ICH (OR, 1.43; [95% CI, 0.86-2.38]; =0.17). Conclusions Lower levels of genetically proxied VitD levels are associated with higher ICH risk. These results provide evidence for a causal role of VitD metabolism in ICH.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333362 | PMC |
http://dx.doi.org/10.1161/JAHA.121.024141 | DOI Listing |
Mol Biol Rep
December 2024
Department of Physiology, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Background: The role of 1,25-dihydroxyvitamin-D3 (VitD) and sirtuin-1 (SIRT1) in mitigating pathological cardiac remodeling is well recognized. However, the potential for SIRT1 to mediate the inhibitory effects of VitD on angiotensin II (Ang II) -induced hypertrophy in H9c2 cardiomyoblasts remains unclear.
Methods: H9c2 cardiomyoblasts were exposed to Ang II or a combination of VitD and Ang II, both in the absence and presence of SIRT1-specific siRNA.
Curr Issues Mol Biol
December 2024
Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.
Studies suggest that vitamin D (VitD) may reduce oxidative stress (OS) in multiple sclerosis (MS) patients. This study aimed to compare the effects of various VitD doses on OS in relapsing-remitting MS (RRMS). A 6-month supplementation was introduced using two doses of VitD: 2000 IU/day in the high-dose group (HD, = 23) and 15,960 IU/month in the low-dose group (LD, = 29).
View Article and Find Full Text PDFJDS Commun
November 2024
Institute for Global Food Security, School of Biological Sciences, Queen's University, Belfast, United Kingdom BT9 5DL.
Investigations into the role of vitamin D (vitD) in the immune response of cattle are limited. The objectives of this study were therefore to investigate the association between circulating vitD concentration, tuberculosis (TB) vaccination, and infection outcomes in 24 dairy calves (<8 wk old) that were housed throughout and fed a BW-based allowance. The study design incorporated 2 phases: vaccination (experimental wk 0-52) and experimental infection phase (wk 52-65).
View Article and Find Full Text PDFFront Pharmacol
November 2024
Department of Orthopedic Trauma, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Objective: There is currently no consensus on whether the combination therapy of Vitamin D (VitD) and bisphosphonates offers superior efficacy compared to monotherapy in the treatment of postmenopausal osteoporosis. The aim of this study is to conduct a meta-analysis of recent relevant research to synthesize the available evidence and further investigate whether the combined use of VitD and bisphosphonates is superior to monotherapy in treating osteoporosis in postmenopausal women.
Methods And Results: We systematically searched PubMed, EMBASE, the Cochrane Library, and Web of Science for randomized controlled trials (RCTs) comparing the effects of monotherapy with VitD or bisphosphonates their combination therapy in the treatment of postmenopausal osteoporosis, up to 1 February 2024.
Spine (Phila Pa 1976)
December 2024
Department of Orthopaedic Surgery, Hospital for Special Surgery, Weill Cornell Medicine, New York City, NY, USA.
Study Design: Secondary analysis of a prospective single-center study.
Objective: To analyze the prevalence and risk factors for untreated osteoporosis in patients undergoing lumbar spinal fusion surgery (LFS) and its impact on bone mineral density (BMD) and bone turnover markers.
Background: Osteoporosis is a risk factor for mechanical complications in LFS, which can be mitigated by antiosteoporotic treatment.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!